Interview with the President and CEO: Soligenix, Inc. (NASDAQ:SNGX)
Christopher J. Schaber, Ph.D., has over 27 years of experience in the pharmaceutical and biotechnology industry, and has been Soligenix, Inc.'s President, Chief Executive Officer and a Director since August 2006. He also serves on the board of directors for the Alliance for BioSecurity and BioNJ, and is a member of the corporate councils for both the National Organization for Rare Diseases and the American Society for Blood and Marrow Transplantation. Prior to joining the company, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc. From 1996 to 1998, he was a Co-Founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his B.A. from Western Maryland College, his M.S. in pharmaceutics from Temple University School of Pharmacy and his Ph.D. in pharmaceutical sciences from the Union Graduate School. Profile
TWST: We last spoke to you in 2015. Can you give us a summary update on your late-stage assets and their market potentials?